ClinicalTrials.gg
RecruitingNCT06782997ERGDIABUpdated Jul 28, 2025

Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diabetic Retinopathy.

An observational study in Diabetic Retinopathy, sponsored by CHU de Reims. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by CHU de Reims · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
270
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Diabetic Retinopathy with a site in France — 5 open to participants now, 5 under way, none of them phase 3. Diabetic Retinopathy · France.

Planned enrollment
4th of 11
270 · median 101
Started
2025
the only one that year
Observational
11 of 30
2 open now
Registered
29th of 30
by date
Lead sponsor
4 of 30
CHU de Reims

Among the 30 studies in Diabetic Retinopathy with a site in France, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2025, is one of 11 observational ones, and was the 29th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

5 of the 30 studies in Diabetic Retinopathy with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Diabetic Retinopathy with a site in France, or all of them as a file.
02

Study summary

Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus and the leading cause of preventable blindness in working-age individuals. Early screening for DR is a public health issue. The gold standard is fundoscopy interpreted by an ophthalmologist. In France, in 2020, it was estimated that one-third of diabetic patients had not seen an ophthalmologist in over two years. Recently, a portable electroretinogram (ERG), which provides a physiological and non-invasive assessment of retinal cell function, has been developed. It combines pupillary responses through an infrared-sensitive camera, the implicit time and the response amplitude to brief white light stimuli. The result is expressed as an overall score (DR score), considered abnormal if it is \< 7 or > 23.4. The sensitivity of the ERG for screening diabetic retinopathy is estimated at 80%, and its specificity at 82%, compared to conventional imaging. Additionally, it has been shown that poor glycemic control is associated with an increase in implicit time in preclinical DR. This test could therefore detect earlier changes than imaging results. To date, it is not considered the gold standard in France. The investigators aim to test this hypothesis. The investigators propose a prospective, bi-center study to evaluate the performance of the ERG, performed and interpreted by an Advanced Practice Nurse (APN), compared to the gold standard of retinal imaging (retinography) interpreted remotely by an ophthalmologist.

Read the detailed description

Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus and the leading cause of preventable blindness in working-age individuals. Early screening for DR is a public health issue. The gold standard is fundoscopy interpreted by an ophthalmologist. In France, in 2020, it was estimated that one-third of diabetic patients had not seen an ophthalmologist in over two years. Recently, a portable electroretinogram (ERG), which provides a physiological and non-invasive assessment of retinal cell function, has been developed. It combines pupillary responses through an infrared-sensitive camera, the implicit time and the response amplitude to brief white light stimuli. The result is expressed as an overall score (DR score), considered abnormal if it is \< 7 or > 23.4. The sensitivity of the ERG for screening diabetic retinopathy is estimated at 80%, and its specificity at 82%, compared to conventional imaging. Additionally, it has been shown that poor glycemic control is associated with an increase in implicit time in preclinical DR. This test could therefore detect earlier changes than imaging results. To date, it is not considered the gold standard in France. The investigators aim to test this hypothesis. The investigators propose a prospective, bi-center study to evaluate the performance of the ERG, performed and interpreted by an Advanced Practice Nurse (APN), compared to the gold standard of retinal imaging (retinography) interpreted remotely by an ophthalmologist.

The investigators' study will prospectively include adult patients with type 1 or type 2 diabetes mellitus and without know DR. These patients are followed in both study centers and both examinations (ERG and retinography) will be performed during the hospitalization for the evaluation of their diabetes and complications. Sensitivity and specificity of the ERG performed and interpreted by an APN will be compared to gold standard.

03

Conditions studied

  • Diabetic Retinopathy

Keywords

  • Diabetes mellitus
  • electroretinography
  • screening
  • diabetic retinopathy
  • advanced practice nurse
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with type 1 or type 2 diabetes mellitus and without know DR, followed in both study centers and hospitalized for the evaluation of their diabetes and complications.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients > 18 years old
  • With type 1 or type 2 diabetes mellitus
  • No known diabetic retinopathy
  • Affiliated to a social security system
  • Attending the hospitals of Reims or Charleville Mézières in France during a hospitalization for the evaluation of their diabetes and complications

Exclusion criteria

Exclusion criteria:

  • Known diabetic retinopathy
  • Ongoing pregnancy or within 3 months postpartum
  • Recent cataract surgery (\< 3 months)
  • Photosensitive epilepsy
  • Patients under legal protection
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
270 participants (estimated)
Patient registry
No

Groups and cohorts

  • diabetic Patients

    Any diabetic hospital patient requiring screening for diabetic retinopathy

    Device: Electroretinogram

Interventions

  • DeviceElectroretinogram

    Electroretinogram (RETevalTM devices, LKC Technologies) performed and interpreted by an advanced practice nurse compared to the gold standard (retinography) interpreted by an ophthalmologist

06

What researchers measure

Primary outcomes

  1. Sensitivity of the electroretinogram

    Sensitivity of the electroretinogram, performed and interpreted by an advanced practice nurse, for screening diabetic retinopathy compared with the gold standard (retinography interpreted by an ophthalmologist).

    Time frame: during the patient's hospitalization, an average of 1 week

Secondary outcomes

  1. Specificity, positive predictive value and negative predictive value of the ERG

    Specificity, positive predictive value and negative predictive value of the ERG performed and interpreted by an advanced practice nurse, for screening diabetic retinopathy compared with the gold standard

    Time frame: during the patient's hospitalization, an average of 1 week

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 75 non-industry observational studies under Diabetic Retinopathy, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13. This study's planned 18 months is below that.

Counting every sponsor, half of 92 studies reached it within 28 months; a quarter within 12 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 20, 2025
StartActual
Jun 17, 2025
Primary completionEst.
Dec 17, 2026
CompletionEst.
Dec 17, 2026
Last update
Jul 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06782997
Lead sponsor
CHU de Reims
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Jun 17, 2025
Primary completion
Dec 17, 2026 (estimated)
Completion
Dec 17, 2026 (estimated)
Last update
Jul 28, 2025

Study contacts

Jenny FONTAINE
Contact
jfontaine@chu-reims.fr
03 26 78 80 21 ext. 0033

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion